FINHUB Insights

RMD · Q2 FY26 · Oct 1 – Dec 31, 2025

ResMed Q2 FY26: where the revenue came from and where it went

ResMed Q2 FY26: revenue $1.4B (+11% year over year). Net profit $0.4B. Largest cohort Sleep and Breathing Health $1.3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2025
Reported
Jan 30, 2026 10-Q
Sankey diagram of ResMed's income statement for Q2 FY26: revenue of $1.4 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.4B +11% year over year
Gross profit$0.9B 62% margin
Operating profit$0.5B 35% margin
Net profit$0.4B 28% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Dec 31, 2025).
ItemValueShare of revenueYear over year
Revenue 1.4 100% +11%
Sleep and Breathing Health 1.3 93% +12%
Residential Care Software 0.2 14% +7%
Cost of revenue−0.536%
Gross profit0.962% margin+3pp
Research & development−0.16%+0pp
SG&A−0.320%+1pp
Other−01%+0pp
Operating profit0.535% margin+2pp
Tax−0.1
Net profit0.428%+1pp
Filing on EDGAR More quarters of RMD

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters